Adalvo has successfully launched Adapalene/Benzoyl Peroxide (A/BPO) 0.1%/2.5% gel in the United Kingdom, based on the reference product Epiduo Gel.
Developed with a clearly defined IP pathway, this complex combination retinoid represents Adalvo's expertise in technically challenging formulations.
Adapalene + Benzoyl Peroxide shows superior efficacy in treating mild-to-moderate acne compared to single-ingredient monotherapies due to complementary mechanisms of action.
Acne affects over 80% of people at some point in their lives. In the UK alone, acne accounts for 3.5 million GP consultations and 70,000 specialist referrals annually, representing a large unmet need and commercial opportunity.
The retinoid market shows robust growth worldwide. According to IQVIA, global sales of Epiduo Gel reached $152 million in 2023, and the UK retinoid market grew by 25% between 2023-2025, reflecting a growing demand for this therapeutic class.
The successful launch strengthens Adalvo's dermatology portfolio and readies the company for expansion into other European and international markets.
For licensing or commercial opportunities within Adalvo's dermatology portfolio, contact the team today.